in

Weight-loss jabs like Wegovy and Ozempic reduce risk of some of the most common and deadly cancers, study says


Revolutionary weight-loss injections such as Wego and Ozempic reduce the risk of some of the most common and deadly cancers, a major study suggests.

Obese patients taking drugs originally designed to help diabetics were almost a fifth less likely to develop cancers including breast, bowel, pancreatic and ovarian cancers.

American researchers also concluded that these patients were half as likely to die within 15 years compared to obese patients who did not take the weekly injections. Experts believe this is because the drugs, known as GLP-1 agonists, protect against obesity-related cancers such as thyroid, kidney and liver.

Obesity is thought to be the second most common cause of cancer in the UK after smoking and is responsible for around one in 20 new cases each year.

A study presented at the American Society of Clinical Oncology conference in Chicago is the latest to show that GLP-1 agonists have significant health benefits beyond weight loss.

Revolutionary weight-loss injections like Wego’s and Ozempic’s could reduce the risk of some of the most common and deadly cancers (Pictured)

It was originally developed as a treatment for diabetes, but in recent years it has become one of the world's most sought-after weight loss drugs, including for celebrities (Pictured)

It was originally developed as a treatment for diabetes, but in recent years it has become one of the world’s most sought-after weight loss drugs, including for celebrities (Image)

Last year, studies concluded that semaglutide – the active ingredient in Wegovy and Ozempic – reduces the risk of heart failure and kidney failure.

It was originally developed as a treatment for diabetes, but in recent years it has become one of the world’s most sought-after weight-loss drugs, with a number of celebrities – including Elon Musk and Boris Johnson – revealing they are taking it in a bid to lose weight. down.

Recommended Article
Jenna Ortega expresses her support for Palestine and demands to know 'where the humanity is' - just months after Scream VII actress Melissa Barrera was fired for criticizing Israel

Research suggests that, on average, patients taking semaglutide lose a fifth of their body weight.

Last year, an even more potent GLP-1 agonist, called tirsepatide, was launched.

In a new study, the health status of 273 obese patients with a GLP-1 agonist was monitored over 15 years. Their results were compared with around 400 patients who underwent weight-loss surgery – known as bariatric surgery – as well as 20,000 obese people who did not undergo either.

While the GLP-1 agonist patients did not lose as much weight as those who underwent bariatric surgery, both groups were 19 percent less likely to develop obesity-related cancers compared to those who did not receive any treatment.

«Weight loss seems to be driving this reduction in cancer to a large extent,» says Dr. Cindy Lin, a sports and exercise medicine expert at Case Western Reserve University in Ohio.



What do you think?

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

GIPHY App Key not set. Please check settings

Zhilei Zhang KNOCKING OUT Deontay Wilder in the fifth round with an explosive right hook as Frank Warren’s Queensbury complete a 5v5 clean sweep against Eddie Hearn’s Matchroom

Jennifer Lawrence keeps it low-key in casual double denim as she and husband Cooke Maroney are spotted at JFK Airport in NYC.